Photo-induced anticancer activity and singlet oxygen production of prodigiosenes by Savoie, Huguette et al.





Huguette Savoie,a Carlotta Figliola,b Estelle Marchal,b Bry W. Crabbe,c  
Geniece L. Hallett-Tapley,*c Ross W. Boyle,*a Alison Thompson*b 
 
aDepartment of Chemistry, University of Hull, Cottingham Road, Hull, HU6 7RX, UK; 
bDepartment of Chemistry, Dalhousie University, PO BOX 15000, Halifax, NS, B3H 4R2, 
Canada; cDepartment of Chemistry, St. Francis Xavier University, PO Box 5000, Antigonish, 
NS, B2G 2W5, Canada. 
Abstract 
The photo-induced cytotoxicity of prodigiosenes is reported. One prodigiosene represents a 
synthetic analogue of the natural product prodigiosin, and two are conjugated to molecules that 
target the estrogen receptor (ER). A comparison of incubation and irradiation frameworks for the 
three prodigiosenes is reported, with activity against ER- and ER+ lines explored. Furthermore, 
the ability of the three prodigiosenes to photosensitise the production of singlet oxygen is 
demonstrated, shedding mechanistic light onto possible photodynamic therapeutic effects of this 
class of tripyrroles. 
Introduction 
Photodynamic therapy (PDT) is a light-induced, non-invasive cancer treatment, which is 
effective for both tumour cell killing and ablation.1-7 PDT usually involves the use of a 
photosensitizer (PS), which, upon irradiation of the tumour site with light, triggers a series of 
photochemical and photobiological reactions generating reactive oxygen species (ROS), such as 
singlet oxygen (1O2), that are directly toxic to cells.8 PDT also induces vascular damage and 
blood flow stasis that deprive the tumour cells of their nutrients, thus indirectly leading to both 
apoptosis and inflammation around the tumour site and stimulating an immune response (both 
local and systemic).9-14 Advantages of localizing light irradiation to the cancerous area include 
limited damage to healthy tissues and minimized long-term systemic toxicity. However, PDT is 
not without its drawbacks. The most common side-effect, sunlight sensitivity, can last from a 
few days to 4-6 weeks due to the accumulation of PS in the skin. PDT can be employed to treat a 
wide range of solid tumours (e.g. brain, breast, lung, pancreas, prostate) and more advanced  
cancers when combined with other therapies (chemotherapy, radiotherapy, surgery). In order to 
ensure an efficient PDT regime, the PS should absorb light in the range of 650-800 nm (near-
infrared region, NIR), where light penetration through the human tissues is optimal,6 and 
effectively produce 1O2.15, 16 Therefore, the PS should have high quantum yields of triplet 
formation (>50%), long triplet lifetimes (microseconds) and low quantum yields of 
photobleaching.16, 17 Furthermore, the PS should ideally be chemically pure, accumulate 
selectively in the tumour area, have no dark toxicity and be cleared from the body within days in 
order to minimize skin phototoxicity.15 
Tetrapyrrole-based photosensitizers, including porphyrins, chlorins and phthalocyanines 
with their highly conjugated structures absorbing in the red/NIR, have been studied as PS for 
PDT for many years. Several have been used clinically5, 17 (e.g. porfimer sodium, verteporfin, 
temoporfin).17-21 The addition of heavy atoms, usually transition metals,22 the encapsulation of 
the PS into nanoparticles23 and the use of supramolecular structures24 are among the strategies 
employed to design new tetrapyrrolic PS for PDT. Furthermore, conjugation to bioactive 
molecules, such as antibodies,25 significantly increases the selectivity of the PDT agent towards 
the targeted cancerous cells.18, 26, 27 However, cyclic tetrapyrrolic compounds are often 




synthetically challenging and structure modifications can be rather difficult. Consequently, 
recent studies have been focused on other pyrrolic structures such as 4,4-difluoro-4-bora-3a,4a-
diaza-s-indacenes (BODIPYs) and aza-BODIPYs.17, 28 
Prodigiosin is a tripyrrolic, red pigmented natural product produced by certain strains of 
Serratia and Streptomyces bacteria (1, Figure 1).29, 30 It exhibits a multitude of biological 
responses including immunosuppressive,31 antimicrobial32-35 and anticancer properties36, 37 
through several modes of action, e.g. H+/Cl- exchange,38-41 Cu-mediated DNA cleavage42-44 and 
signal-transduction interference.45-47 However, clinical applications have been limited due to 
poor selectivity.29 Derivatives of prodigiosin, namely prodigiosenes,48 featuring various 
modifications on the pyrrolyldipyrrin core of the natural product, have been shown to maintain 
the anticancer activity of the parent compound, as well as result in a reduced toxicity profile.49-56 
Despite the similarity of the tripyrrolic core with both porphyrins and BODIPYs, only a 
few studies have reported the use of prodigiosin and its synthetic derivatives as potential PS for 
PDT treatments. In 1967 the exposure of colourless mutant Sarcina lutea cells to prodigiosin 
causes cell death under irradiation with visible light was demonstrated.57 Forty years later the 
anticancer activity of prodigiosin 1 and the synthetic analogues 2-4 against the HL-60 cancer 
cells after 30 minutes of irradiation with visible light (Figure 1) was reported.58, 59 The dark 
cytotoxicity, featured by the natural product,29 was shown to be prevented using either an N-
methyl group on the C-ring (2) or a phenyl group as the A-ring (3 and 4), which both block the 
coordination of metal cations, usually copper, and subsequent DNA damage.42-44 Although 
synthetic analogues 2-4 were demonstrated to exhibit a significant photo-induced cytotoxicity (in 
the case of analogue 4, the IC50 value is almost equal to that of the natural product 1, 3.6 and 2.5 
μM respectively),58 the experimental details for assessing the anticancer activity do not include 
critical details such as fluence. Furthermore, suggestions as to underlying mechanistic 
considerations are sparse.58, 59 
 
Figure 1. Prodigiosin 1 and synthetic prodigiosenes 2-4 
Conjugation of potential drugs to bioactive molecules60-66 represents a very effective 
strategy67-69 to target specific cancerous tissues,70 and accordingly minimize toxicity towards 
healthy cells. Previously, we reported the synthesis of the first series of prodigiosenes conjugated 
to estradiol and 4-hydroxytamoxifen derivatives.51 Herein, we report the investigation of the 
anticancer activity of two representatives of this class, conjugates 5 and 6, against ER+ (T-47D) 
and ER- (MDA-MB-231) breast cancer cell lines, in the dark and under visible light irradiation 
(Figure 2). The tripyrrolic core of prodigiosene serves as chromophore, while the estradiol- and 
tamoxifen-moieties are intended to function as bio-vectors to target cancer tissues 
overexpressing estrogen receptors.70-74 Ready available synthetic prodigiosene 7,52 featuring only 
an extra methyl group on the C-ring compared to the natural product, is used as a control through 
which to assess the selectivity of 5 and 6 towards the targeted ER+ breast cancer cells (Figure 2). 





Figure 2. Synthetic prodigiosenes discussed herein 
Results and discussion 
In order to study the effects of conjugating prodigiosenes to the bio-vectors estradiol and 4-
hydroxytamoxifen, conjugates 5 and 6, along with control compound 7, were incubated with 
ER+ (T-47D) and ER- (MDA-MB-231) breast cancer cell lines at a range of concentrations for 
24, 48 and 72 hours. In order to solubilise them 5, 6, and 7 were dissolved in DMSO and diluted 
with media to the appropriate concentrations. Cells were then either irradiated with visible light 
(400 – 700 nm; 10 J cm-2) or protected from light, and cell viability was assessed 24 hours later 
by MTT assay.75 Cytotoxicity results are shown, graphically, in Figure 3. The native toxicity of 
non-conjugated prodigiosene 7 (Figure 3, bottom) results in 90% or greater cell killing for both 
ER+ and ER- cells at the highest concentration (10 µM), and shows little difference between 
irradiated and non-irradiated cells. Some differentiation between ER+ and ER- cells can be seen 
at lower concentrations, but as 7 has no targeting component this may simply be due to 
differences in metabolism between the two cell lines. 
A more complicated set of results was observed for the prodigiosin conjugates 5 and 6. 
Estradiol conjugate 5 demonstrated negligible toxicity (Figure 3, top), either with or without 
light, against the ER- cell line; this contrasts with the same conjugate for ER+ cells, where at the 
shortest incubation time (24 hr), and highest doses (10 and 5 µM), very little or no toxicity is 
seen in the absence of light. However, at the same time point cell killing is increased by 
approximately 30% upon irradiation. Longer incubation times result in a steady increase in 
toxicity for non-irradiated cells and a decrease in the cell killing enhancement gained from 
irradiation. The increase in “dark” toxicity with time may be associated with a requirement for 
internalisation, whereas light-mediated toxicity resulting from ROS mediated damage would be 
expected to be more immediate. However, this could be masked at later time points by the 
inherent cytotoxicity of the prodigiosin, as shown for the non-conjugated analogue. Thus, the 
conjugation of estradiol “protects” both cell lines from “dark” toxicity at early time points, but 
this is re-established with longer incubations. 
4-Hydroxytamoxifen conjugate 6 shows a similar patter of activity to 5 in terms of 
“protection” of the cells c.f. the toxicity of free prodigiosin 7. However, the enhancement of 




cytotoxicity mediated by light is more extreme at the two higher concentrations (10 and 5 µM) – 
approximately 70% and 80%, respectively. Disappointingly, this photo-enhancement of cell 
killing is seen for both ER+ and ER- cells, suggesting the effect is general, and not associated 
with active targeting by the 4-hydroxytamoxifen. 
Taking all the results together, the conjugation process significantly reduces the inherent 
cytotoxicity of prodigiosin, especially at shorter incubation times and higher concentrations and, 








Figure 3. Cytotoxicity results for prodigiosenes 5-7 against ER- (MDA-MB-231) and ER+ (T-
47D) cell lines, either irradiated (IRR) or non-irradiated (NI), as a function of incubation time 
and concentration (M). 
In an effort to gain a more thorough understanding of the mechanism (type I or II)6, 7 of 
the phototoxicity of conjugated 5 and 6, and the unconjugated prodigiosin 7, a UV-vis analysis 
was carried out using 9,10-dimethylantracene (DMA), as a diagnostic tool.76 DMA absorbs in a 
region that is transparent to molecules 5, 6 and 7 and has been found to rapidly scavenge 1O2 




(type II mechanism) to generate an endoperoxide (Figure 4). This endoperoxide remains 
undetectable in the regions of both the photosensitizers of interest and, most importantly, the 
DMA probe. By monitoring the disappearance of DMA, using absorption spectroscopy as a 
function of time, endoperoxide formation and, thus, 1O2 generation can be estimated.76, 77 
 
Figure 4. DMA photo-oxidation reaction. 
Prior to introduction of DMA into the reaction mixture, the photostability of 5, 6 and 7 was 
assessed via 480 nm LED excitation. This LED light source was chosen as it is close to the 
maximum spectral absorption the photosensitizers of interest. Figure 5 illustrates absorption 
decreases of 5 (λmax = 473 nm ), 6 (λmax = 453 nm) and 7 (λmax = 473 nm) by 22 %, 51 % and 
63%, respectively, following 120 min of irradiation. Previous work59 has related photoactivity 
and, thus, photocytotoxicity, of prodigiosin analogues to absorption loss with exposure to visible 
light. However, it has also been shown that methylene blue photosensitizers exhibit little change 
in absorption with extended visible light irradiation.78 Given the seemingly contradictory nature 
of these contributions, it is possible that observed variations in dye absorption, as a function of 
extended irradiation, may be a hybrid of the two and attributed to both photoactivity and 
photostability of the molecule. The λmax for the unconjugated control (7) is nearly at the λmax of 
the LED excitation source, resulting in larger absorption of the light energy. Conversely, 
prodigiosene 6 is observed to have a λmax ~30 nm blue shifted from the 480 nm light source, 
resulting in decreased light absorption by the molecule and may be responsible for the 
marginally smaller decrease in absorption observed in Figure 5b. Furthermore, 5 clearly shows 
lower absorption at 480 nm (Figure 5a) as compared to solutions of 6 and 7 at the same 
concentration. The diminished molecular absorptivity at the excitation wavelength likely 
contributes to the smaller % loss of 5 over 120 min irradiation. Thus, the observed decrease in 
the absorption intensity at λmax for 5, 6 and 7 is proposed to be due to, in part, photobleaching of 
the molecule as a result of extended LED light exposure, as well as the photoresponse of the 
molecule at λmax of LED light source. 




   




Figure 5. Time monitored absorption of 10 µM(a) 5, (b) 6 and (c) 7 in CH3CN following 480 nm 
LED irradiation. 
 
 In order to discern the mechanism responsible for the observed photoactivity of 
syntheized prodigiosenes presented in Figure 2, DMA was added to allow for both 1O2 detection 
and 1O2 quantification. Importantly, in the absence of either 6 or 7, no decrease in DMA 
absorption was observed, indicating that the probe molecule is photo-inactive at the chosen 
excitation wavelength of 480 nm (see Figure S1). Figure 6 illustrates the time-monitored UV-
visible absorption spectra obtained for conjugated molecules 5 and 6 following exposure to 480 
nm LED light in the presence of DMA. The DMA absorption (398 nm) decreases 32 and 15% 
after 20 min of irradiation of 5 and 6, respectively.  DMA absorption continued to diminish over 
120 nm, after which time absorption due to 5 and 6 was negligible. The diminished DMA 
absorption following excitation of the synthetic prodigiosenes strongly suggests that 1O2 
generation from the these molecules is responsible for the observed decrease due to the known 
capability of the probe anthracene to rapidly trap 1O2 and strongly suggests that a type II 
mechanism is responsible for the observed photocytotoxicity illustrated in Figure 3. 
The photoactivity of 7 was also examined in the presence of the DMA (Figure S2) to 
allow for direct comparison of 1O2 yields generated from both the unconjugated control and the 
corresponding estradiol and hydroxytamoxifen derivatives (5 and 6). The DMA absorption at 
398 nm decreases a minimal 5 % following exposure of 7 to 20 min of 480 nm LED light. This 
result suggests that prodigiosene conjugation is highly influential on the light-induced toxicity of 
the photosensitizer. 
 




      
 
Figure 6. UV-visible spectra of 10 µM (a) 5 and (b) 6 and 70 µM DMA collected in CH3CN 
over 120 min of 480 nm LED light exposure 
The photoefficiency, or quantum yield, of 1O2 (ΦΔ) is commonly used to assess the 
overall phototoxicity of a given photosensitizer and provides a quantitative means of assessing 
the capacity of a molecule to facilitate cell death. ΦΔ of  5 and 6 and 7 was calculated using Rose 
Bengal as a reference actinometer (ΦΔ in CH3CN = 0.54).79 to evaluate the overall efficacy of 
visible light-induced phototoxicity of the discussed synthetic prodigiosenes. The time-resolved 
absorption spectra of DMA following 480 nm irradiation of Rose Bengal is shown in Figure S3 
and the method used for ΦΔ calculation is discussed in the Supporting Information. ΦΔ for 5, 6 
and 7 were calculated as 0.32, 0.69 and 0.38, respectively. These values closely mirror the results 
observed in Figure 3, with 6 exhibiting the most pronounced light-induced cytotoxicity and 5 the 
least. These behaviours align well with the calculated efficiencies of the synthetic prodigiosenes 
to generate cytotoxic 1O2. The smaller ΦΔ for 5 and 7 may be a consequence of lower 
photoresponse or bio-vector conjugation, respectively. Table 1 summarizes the photophysical 
properties determined for 5, 6 and 7 and, again, strongly suggests a type II phototoxicity 
mechanism. 
 
Table 1. Photophysical properties calculated for 5, 6 and 7 in CH3CN 
Prodigiosene λmax (nm) ΦΔ 
5 473 0.32 
6 453 0.69 
7 473 0.38 
 
Conclusions 
The results of our photocytotoxicity studies for prodigiosenes with, and without, conjugated ER 
receptor targeting molecules, confirms the previously reported photodynamic activity of this 
class of chromophore. However, while prodigiosenes undoubtedly exhibit both direct anti-cancer 
and photodynamic properties, their practical applications in cancer therapy have been hindered 
by a lack of selectivity for specific cancers. Comparison of the behaviour of prodigiosenes 
conjugated to ER-targeting molecules estradiol and hydroxytamoxifen (5 and 6) with the same 
tripyrrolic chromophore without active targeting (7) shows that, while the general cytotoxicity is 
reduced for 5 and 6, relative to the core tripyrrolic unit of 7. Interestingly, enhancement of 
anticancer activity upon irradiation is also observed, especially for conjugates 5 and 6 at shorter 




incubation times and higher concentrations. By using 9,10-dimethylanthracene as a 1O2 
scavenger, photophysical properties of both the unconjugated (7) and conjugated (5 and 6) 
photosensitizers clearly suggest that 1O2 is produced following visible light irradiation. This 
suggests that a type II mechanism is responsible for the observed phototoxicity of prodigiosenes. 
The photophysical studies further corroborate that conjugation of prodigiosenes to 
hydroxytamoxifen (6) exhibits enhanced, light-dependent, anticancer activity through increased 
photoefficiency of 1O2 formation. These results suggest that suitable prodigiosin conjugates may 




Compounds 5,51 651 and 754 were prepared according to literature procedures. 
Photocytotoxicity Assay 
Cells (5 x 103; 100 µl /well) were plated into 96-well plates in duplicate and left overnight to 
attach in an incubator set at 37 ºC and 5% CO2. The media was carefully removed the next day 
and medium only (controls), or medium plus dilutions of prodigiosin compounds, were added to 
each seeded well. The plates were then incubated for 24, 48 or 72 hrs. At the appropriate time 
point, the two duplicate plates were taken out. One was kept in the dark while the other one was 
irradiated with broad band visible light (400 – 700 nm, Oriel light system: 100 Quartz Tungsten-
halogen lamp housing powered by a 1100 W radiometric power supply) at a dose of 10 J cm-2, 
after which both plates were returned to the incubator. 24 hrs later an MTT assay75 was 
performed and the colorimetric changes read (Biotek plate reader). Results were expressed as a 
% of the cells only readings taken as 100% cell survival. 
Photophysical Studies 
9,10-Dimethylantracene (DMA) was purchased from Sigma-Aldrich and used as received. 
HPLC-grade CH3CN used in sample preparation and analysis was purposed from Fisher 
Chemicals Canada and used as received. Samples were prepared in 1 cm x 1 cm quartz cuvettes. 
For each trial 70 µM DMA, 10 µM photosensitizer, or a combination of the two, were prepared 
in a 3 mL solution of CH3CN and exposed to 480 nm LED light (Mouser, Inc.) set at a power of 
1.1 W. UV-visible spectra of the sample were taken every 20 min using a Cary 100 UV-visible 
spectrophotometer in dual beam mode. Concentration of the photosensitizers was chosen based 
on the largest concentration used in the photocytotoxicity studies. 
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